Centre for Cancer Biomarkers & Biotherapeutics

The Centre for Cancer Biomarkers & Biotherapeutics is located in the Barts Cancer Institute, a CRUK Centre of Excellence dedicated to delivering world-leading research. We comprise a multidisciplinary team of surgeons, clinicians, pathologists, basic scientists, biobanking professionals and bioinformaticians; working together towards a common goal.

Our overarching vision is to apply our skills and expertise in developing innovative personalised diagnostic, prognostic and therapeutic strategies. Research focuses on the discovery of new biomarkers for earlier diagnosis, monitoring disease progression and response to treatment, and identifying those individuals at risk of disease, and developing targeted treatments.

Our activities are enhanced by our involvement with local and national biobanks: within the Centre, we have biobanking professionals for specimen management and bioinformaticians for analysing molecular data. Our diversity of research specialities offers an unparalleled opportunity to create a biobanking system in which clinical, molecular and pathologic data are linked.

We are committed to enhancing the teaching experience both for students and the general public through our teaching and outreach activities.

Contact us

Centre Lead: Professor Nick Lemoine

Deputy Centre Lead: Professor Claude Chelala

John Vane Science Centre,
Charterhouse Square,
London EC1M 6BQ

Recent Publications

  • Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial. JAMA Oncol (2019). PMID: 31465093
  • Non-invasive Detection of Clinically Significant Prostate Cancer Using Circulating Tumor Cells. J Urol (2019). 203(1):73-82. PMID: 31389764
  • Systemic delivery and SPECT/CT in vivo imaging of 125I-labelled oncolytic adenoviral mutants in models of pancreatic cancer. Sci Rep (2019). 9(1):12840. PMID: 31492884
  • AGR2, a unique tumor-associated antigen, is a promising candidate for antibody targeting. Oncotarget. (2019). 10(42):4276-4289. PMID: 31303962

Latest News

  • Dr Dayem Ullah and Professor Claude Chelala conducted a population-based study to explore the risk factors associated with COVID-19 susceptibility and survival in patients with a history of diseases of the liver, pancreas or biliary system - also known as hepato-pancreato-biliary diseases - in East London. Find out more.
  • Researchers have released a web-based tool called SNPnexus COVID (https://www.snp-nexus.org/v4/covid/) to streamline the analysis of host genetic sequencing data and allow for the identification and prioritisation of genetic variants that may impact an individual’s susceptibility to and the severity of COVID-19 infection. Read the full story.
  • Congratulations to Professor Nick Lemoine who has been named in the Evening Standard's Progress 1000 list (2019), which recognises London's most influential people.

Areas of focus

Solid Tumour Research
QMUL lab image
Biobanking
Biobanking
Molecular Imaging
Molecular imaging
Translational Bioinformatics
Bioinformatics
Oncolytic Immunotherapy
Abstract background virus. The concept of science and medicine, reducing immunity in the body. Influenza virus, hepatitis virus, cells that infect the living organism. 3d illustration
Clinical Translation
IMG_0338_cropped

Schmid | Powles | Berney | Szlosarek